Skip to content

    Park Medi World Q1 FY27 earnings call

    PARKHOSPS
    Healthcare·4 Aug 2026
    Management Summary

    Park Medi World Limited reported a strong Q1 FY27 with robust revenue, EBITDA, and PAT growth, driven by operational ramp-up and strategic acquisitions. The company expanded its bed capacity significantly and outlined clear growth plans for FY27 and FY28, funded by internal accruals and IPO proceeds. While occupancy moderated due to new capacity additions, operational metrics like ARPOB showed healthy improvement, and management expressed confidence in maintaining margins and achieving ambitious financial targets.

    Highlights

    6
    • Revenue from operations of ₹476 crores, up 19% year-on-year, driven by steady patient volume and ramp-up at newer hospitals.

    • Operating EBITDA stood at ₹126 crores, a 20% year-on-year growth, with a margin of 26.5% (improvement from 26.3% in Q1 FY26).

    • PAT came in at ₹89 crores, a 35% year-on-year growth, with a PAT margin of 18.6% (expansion of 220 basis points YoY).

    • Total bed capacity stood at 3,960 beds as of June 30, 2026, up 32% year-on-year.

    • ARPOB for the quarter was ₹30,444, an increase of 12% year-on-year from ₹27,221 in Q1 FY26.

    • Successfully commissioned The Medicity Hospital, Rudrapur (330 beds) and announced acquisition of Mehar Hospital, Zirakpur (150 beds).

    Concerns

    2
    • Network occupancy for Q1 FY27 stood at 56%, down from 68% in Q1 FY26, reflecting the step-up in capacity over the past 12 months.

    • Fuller impact of CGHS rate revision (7-7.5% benefit) will be visible from Q2, as Q1 benefit was partially offset by CAPEX spending for upgrades.

    Key financials

    Single quarter

    09 metrics
    1. 01Revenue from Operations₹476 Cr+19%YoY
    2. 02Operating EBITDA₹126 Cr+20%YoY
    3. 03EBITDA Margin26.5%
    4. 04PAT₹89 Cr+35%YoY
    5. 05PAT Margin18.6%

    Capital allocation

    5
    high confidence
    CategoryHeadline
    Capex

    ₹767 crores

    largely through internal accruals and IPO proceeds, without recourse to any fresh debts

    Debt

    Net ₹25.6 crores

    M&A

    The Medicity Hospital, Rudrapur, Uttarakhand

    acquisition · closed · Consideration ₹NaN (cash)

    M&A

    Mehar Hospital, Zirakpur

    acquisition · announced · Consideration ₹NaN

    Liquidity

    Liquidity disclosed

    Fixed deposit stood at INR300 crores and net worth at Rs.2,100 crores. Growth plan fully funded through internal accruals and IPO proceeds.

    Guidance & targets

    24
    CategoryTargetPriority
    Revenue
    FY27 Revenue
    ₹2,080 crores
    High
    Revenue Growth
    FY27 Revenue Growth
    24%
    High
    EBITDA
    FY27 EBITDA
    ₹530 crores
    High
    EBITDA Growth
    FY27 EBITDA Growth
    25%
    High
    PAT
    FY27 PAT
    ₹360 crores
    High
    PAT Growth
    FY27 PAT Growth
    32%
    High
    ARPOB Growth
    ARPOB Growth
    10-12%
    High
    EBITDA Margin
    Blended EBITDA Margin
    26.7%-27%
    High
    EBITDA Margin
    EBITDA Margin for hospitals > 60% occupancy
    30-31%
    High
    EBITDA Margin
    EBITDA Margin for hospitals < 60% occupancy
    15-20%
    High
    Occupancy Rate
    Full-year FY27 Occupancy
    Moderate from 64%
    Medium
    CGHS Rate Revision Benefit
    CGHS Rate Revision Benefit
    7-7.5%
    High
    Bed Capacity
    Total Bed Capacity
    4,740 beds
    High
    Bed Capacity
    Total Bed Capacity
    5,740 beds
    High
    Payer Mix
    Government vs Self-pay/TPA Split
    70:30
    High
    PAT Margin
    PAT Margin
    17-18%
    High
    Rudrapur Financials
    Rudrapur Revenue (FY1)
    ₹100 crores
    High
    Rudrapur Financials
    Rudrapur EBITDA (FY1)
    ₹20-22 crores
    High
    Rudrapur Financials
    Rudrapur PAT (FY1)
    ₹12-13 crores
    High
    Rudrapur Financials
    Rudrapur Revenue (FY2)
    ₹140 crores
    High
    Rudrapur Financials
    Rudrapur EBITDA (FY2)
    ₹35-36 crores
    High
    Rudrapur Financials
    Rudrapur PAT (FY2)
    ₹21-22 crores
    High
    Zirakpur Financials
    Zirakpur Revenue (FY1)
    ₹70-75 crores
    High
    Zirakpur Financials
    Zirakpur EBITDA (FY1)
    25-26%
    High

    What to watch in Q2 FY27

    5

    FY27 Occupancy Rate

    next quarter
    Current56% (Q1 FY27)
    TargetStabilization/Improvement from 56%

    Why it matters

    Occupancy rate is a key driver for hospital revenue and profitability, especially with significant new bed additions.

    Network occupancy for the quarter stood at 56% compared to 68% in Q1 FY'26. This reflects the step-up in capacity over the past 12-months. We expect full-year FY'27 occupancy to moderate from the FY'26 figures of 64%, largely on account of the addition of significant new capacity of 1,490-beds in calendar year 2026.

    Risks & concerns

    4
    RiskSeverity

    Moderated occupancy due to new capacity

    Network occupancy for Q1 FY27 stood at 56%, down from 68% in Q1 FY26, reflecting the significant step-up in capacity over the past 12 months (960 beds added).Management acknowledged

    medium

    CGHS rate revision benefit not fully flowing to bottom line

    While CGHS rate hike provides 7-7.5% revenue benefit, it will be utilized for upgrading equipment and CAPEX spending, not directly translating to higher EBITDA/PAT.Management acknowledged

    low

    Management bandwidth for rapid integration of new assets

    Analyst questioned if rapid expansion could strain management; management stated they continuously train second-line management for smooth transitions.Analyst acknowledged

    low

    Diminishing returns with rapid base expansion

    Analyst asked if incremental economics of new beds would diminish; management believes methodical expansion and densification will ensure attractive returns on invested capital.Analyst downplayed

    low

    Q&A highlights

    8

    “As far as the expected numbers for FY'27 in terms of the revenue, we are expecting a top line of Rs.2,080 crores and with EBITDA of Rs.530 crores and a PAT of Rs.360 crores. So, what we are expecting a growth in compared to last year, revenue growth is 24% and EBITDA growth will be 25% and the PAT growth staggering at 32%.”

    Management provided specific numerical guidance for key financial metrics for the full fiscal year, indicating strong growth expectations.

    asked by Anshul Agrawal

    3 min read7 chapters

    Detailed Narrative

    01

    Q1 FY27 Financial Performance Highlights

    Park Medi World Limited reported strong financial results for Q1 FY27, with revenue from operations growing 19% year-on-year to ₹476 crores. Operating EBITDA increased by 20% year-on-year to ₹126 crores, achieving a margin of 26.5%, an improvement from 26.3% in Q1 FY26. Profit After Tax (PAT) saw a significant jump of 35% year-on-year to ₹89 crores, with the PAT margin expanding by 220 basis points to 18.6%.

    02

    Strategic Acquisitions and Capacity Expansion

    The company continued its aggressive expansion strategy, acquiring 100% shareholding in The Medicity Hospital, Rudrapur (330 beds) for ₹177 crores, which was commissioned on August 2, 2026. Additionally, it announced the acquisition of Mehar Hospital, Zirakpur (150 beds) for ₹107 crores, scheduled to commission in November/December 2026. A 100-bed extension at Palam Vihar (Park Platinum) is also underway. These additions will bring the total bed capacity to 4,740 by end of FY27 and 5,740 by end of FY28.

    03

    Operational Metrics and Case Mix Evolution

    Operational metrics showed healthy trends, with IPD volumes growing 16% year-on-year to 26,304 patients and OPD volumes up 17% year-on-year to 2,23,446 patients. Average Revenue Per Occupied Bed (ARPOB) increased 12% year-on-year to ₹30,444. The company's focus on high-end tertiary and quaternary care continued, with these specialties contributing approximately 62% of revenue, an increase of 440 basis points year-on-year. Network occupancy for Q1 FY27 stood at 56%, a moderation from 68% in Q1 FY26, attributed to the significant new capacity added over the past 12 months.

    04

    FY27 Financial Outlook and Growth Drivers

    Management provided robust guidance for FY27, targeting a top-line revenue of ₹2,080 crores (24% YoY growth), EBITDA of ₹530 crores (25% YoY growth), and PAT of ₹360 crores (32% YoY growth). ARPOB growth is expected to remain in the 10-12% band, and blended EBITDA margins are projected to hold at 26.7%-27%. The company anticipates the full impact of CGHS rate revisions (7-7.5% benefit) from Q2 FY27, which will be reinvested into equipment and facility upgrades.

    05

    Capital Allocation and Funding Strategy

    The company's CAPEX per bed remains competitive at ₹37 lakhs. Total CAPEX planned for FY27 and FY28 is ₹767 crores for 2,130 beds, averaging ₹36 lakhs per bed. This growth plan, including acquisitions and new facility commissioning, is fully funded through internal accruals and IPO proceeds, with no recourse to fresh debt. Net debt (excluding lease liability) reduced to ₹25.6 crores as of June 30, 2026, from ₹28.2 crores as of March 31, 2026, and fixed deposits stood at ₹300 crores.

    06

    Doctor Retention and Talent Management

    Park Medi World maintains a low attrition rate at the consultant level, attributing it to their unique model where doctors are treated as partners, not just employees. The focus is on patient and attendant satisfaction and high-end clinical outcomes, rather than revenue targets. This approach, combined with competitive pay and ESOPs, helps attract and retain talent, even in Tier-2 and Tier-3 cities, by offering freedom and recognition.

    07

    Payer Mix Evolution and Quality Accreditations

    The current payer mix for Q1 FY27 was approximately 77% from government insurance schemes and 23% from self-pay, private insurance, and TPA. The company aims to shift this mix to a 70:30 split (government:cash/TPA) over the next 12-18 months. All operational hospitals are NABH-accredited, and the recently commissioned Panchkula facility is progressing through its NABH accreditation. The company plans to obtain NABL accreditation for four additional labs in the current financial year, adding to the existing nine.

    This is an AI-generated summary of a publicly available earnings call transcript.